Resources from the same session
How do modern first-line combination regimens affect the therapeutic algorithm in later lines of therapy in metastatic prostate cancer?
Presenter: Karim Fizazi
Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
Resources:
Slides
Webcast
State of the art therapeutic landscape in non-metastatic castration-resistant prostate cancer
Presenter: Wai Kay Kwong
Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
Resources:
Slides
Webcast
Emerging systemic therapies in unresectable bladder cancer: Immunotherapy, kinase inhibitors and antibody-drug conjugates
Presenter: Matthew Galsky
Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
Resources:
Slides
Webcast
Q&A, live discussion and wrap up
Presenter: Ravindran Kanesvaran
Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
Resources:
Webcast